Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 75,262 shares of the stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $33.87, for a total transaction of $2,549,123.94. Following the completion of the sale, the insider directly owned 1,423,659 shares of the company's stock, valued at approximately $48,219,330.33. This trade represents a 5.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Reprogrammed Interchange Llc also recently made the following trade(s):
- On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The stock was sold at an average price of $32.07, for a total transaction of $1,567,709.88.
- On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The stock was sold at an average price of $33.84, for a total transaction of $934,796.16.
- On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The shares were sold at an average price of $37.01, for a total transaction of $2,618,938.63.
- On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The stock was sold at an average price of $37.83, for a total value of $298,894.83.
- On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total value of $1,292,523.33.
- On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The stock was sold at an average price of $39.19, for a total transaction of $54,866.00.
- On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12.
- On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40.
- On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total transaction of $656,000.00.
- On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The stock was sold at an average price of $35.00, for a total transaction of $525,000.00.
Vor Biopharma Trading Down 1.5%
Shares of NASDAQ:VOR traded down $0.49 on Friday, reaching $31.23. The company's stock had a trading volume of 396,470 shares, compared to its average volume of 391,530. Vor Biopharma Inc. has a 52-week low of $2.62 and a 52-week high of $65.80. The company has a market cap of $214.05 million, a P/E ratio of -0.11 and a beta of 2.07. The business has a 50-day moving average price of $37.73.
Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).
Analyst Ratings Changes
A number of research firms recently commented on VOR. Wedbush reaffirmed an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vor Biopharma in a research note on Wednesday. Zacks Research upgraded Vor Biopharma from a "strong sell" rating to a "hold" rating in a report on Wednesday, September 10th. Wall Street Zen cut Vor Biopharma to a "strong sell" rating in a report on Saturday, June 28th. Finally, Stifel Nicolaus raised Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price objective on the stock in a research report on Wednesday, September 24th. Five analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $113.83.
Check Out Our Latest Analysis on Vor Biopharma
Institutional Trading of Vor Biopharma
Several hedge funds have recently modified their holdings of VOR. XTX Topco Ltd bought a new position in shares of Vor Biopharma during the 2nd quarter worth approximately $66,000. Goldman Sachs Group Inc. increased its position in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after purchasing an additional 58,247 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Vor Biopharma during the 1st quarter valued at $140,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Vor Biopharma in the 1st quarter worth $100,000. Finally, Money Concepts Capital Corp raised its stake in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares during the last quarter. 97.29% of the stock is owned by hedge funds and other institutional investors.
Vor Biopharma Company Profile
(
Get Free Report)
Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.